oalib

Publish in OALib Journal

ISSN: 2333-9721

APC: Only $99

Submit

Any time

2019 ( 2 )

2018 ( 61 )

2017 ( 67 )

2016 ( 69 )

Custom range...

Search Results: 1 - 10 of 2133 matches for " MW combination "
All listed articles are free for downloading (OA Articles)
Page 1 /2133
Display every page Item
北斗伪距码偏差对基线解算的影响分析
Influence of BDS Pseudorange Code Biases on Baseline Resolution

唐卫明, 刘前, 高柯夫, 邓辰龙, 崔健慧, 沈明星
TANG Weiming
, LIU Qian, GAO Kefu, DENG Chenlong, CUI Jianhui, SHEN Mingxing

- , 2018, DOI: 10.13203/j.whugis20170110
Abstract: 北斗二代系统伪距码中存在与高度角相关的系统性偏差,该偏差会影响高精度的数据处理。基于Melbourne-Wübbena(MW)组合,分别利用现有的伪距码偏差改正模型和实测基线的双差宽巷模糊度残差,分析了伪距码偏差对基线解算的影响。理论分析表明,随着基线长度的增加,伪距码偏差对MW组合确定双差宽巷模糊度的影响越来越大,对300 km基线的影响可达0.36周。实际算例表明,无论基线长短,地球同步轨道(geostationary earth orbit,GEO)卫星的双差宽巷模糊度残差中始终存在偏差;而对于倾斜地球同步轨道(inclined geostationary orbit,IGSO)和中轨(medium earth orbit,MEO)卫星而言,当基线小于300 km时,双差基本可以消除伪距码偏差,其双差宽巷模糊度固定率基本和GPS一致,但当基线超过300 km时,部分卫星的双差宽巷模糊度残差就会存在明显偏差,其双差宽巷模糊度固定率也较低,此时需考虑伪距码偏差的影响
低高度角双频非差数据的周跳探测方法研究
Cycle-Slip Detection Methods for Dual-frequency Un-difference Data at Low Elevation Angle

范士杰, 陈冠旭, 刘焱雄, 牟春霖
FAN Shijie
, CHEN Guanxu, LIU Yanxiong, MU Chunlin

- , 2016, DOI: 10.13203/j.whugis20140124
Abstract: 针对低高度角双频非差数据测量噪声大、周跳探测容易出现误判和漏判的情况,本文基于电离层残差组合和MW组合进行了周跳探测算法的改进。在电离层残差法的周跳探测中,引入了时间窗口方法,利用周跳检测量的误差分布合理确定判定阈值的大小;在宽巷周跳的探测中,对MW组合方法中的判定条件进行了改进,采用加权递推平滑和时间窗口相结合的方法进行宽巷模糊度的精确估计和精度评价。经IGS站观测数据验证,改进算法取得了较好的周跳探测效果
Single versus combination therapy in acute tocolysis: A prospective randomized controlled trial  [PDF]
Wafa R. Al-Omari, Muzibunnisa A. Begam, Farsana S. Khan, Iman Y. Khudhair, Nicolaas J. Nagelkerke
Open Journal of Obstetrics and Gynecology (OJOG) , 2013, DOI: 10.4236/ojog.2013.32047
Abstract:

This is a prospective controlled randomized trial conducted in 92 women with singleton pregnancies in preterm labor. The tocolytic efficacy and safety of combination atosiban and nifedipine was compared with that of the single agent, atosiban. Both lines of intervention was administered for 48 hours. Progression of labor was assessed by the frequency of uterine contractions and cervical changes. For statistical purpose, intent-to-treat (ITT) analysis was used throughout. Efficacy, as determined by the proportion of women in each group who did not deliver after therapy initiation, was comparable with no significant differences, at 48 hrs (91.5% vs. 91.1%) and at 7 days (90.7% vs. 85.7%) for the atosiban and the combination groups respectively. Safety was assessed by the numbers of adverse events. Maternal side effects were reported more in the combination group (34% vs. 64%; P = 0.006). Perinatal outcomes were similar between the groups. We conclude that the addition of nifedipine did not substantially improve the clinical outcomes beyond that were achieved with atosiban alone. Moreover, it has increased maternal side effects. Future research could focus on combination of other tocolytics.

Inhibition of proteasome by bortezomib increase chemosensitivity of bcr/abl positive human k562 chronic myleoid leukemia cells to imatinib  [PDF]
Baran Yusuf, Coskun Oztekin, Bassoy Esen Yonca
Health (Health) , 2009, DOI: 10.4236/health.2009.14052
Abstract: Chronic myeloid leukaemia (CML) results from a translocation between chromosomes 9 and 22 which generates the BCR/ABL fusion oncopro-tein. BCR/ABL has constitutively tyrosine kinase activity resulting in leukemogenesis. Imatinib, a competitive inhibitor of the BCR/ABL tyrosine kinase, is the common treatment of CML. Despite the outstanding results of imatinib in the chronic phase of CML, cases of treatment failure have been reported, resulting in hetero-geneous molecular response. Bortezomib is a reversible inhibitor of the 26S proteasome in-ducing cell cycle arrest in G2/M phase, apop-tosis by inhibition of NF-kB. In this study, we examined the possible synergistic apoptotic effects of the imatinib/bortezomib combination and the responsible apoptotic mechanisms in-duced by this combination in K562 cells. The results of this study showed increased cyto-toxicity by XTT assay in combination of imatinib and bortezomib as compared to any agent alone. On the other hand, synergistic apoptotic affects of combination of these agents were also con-firmed by changes in caspase-3 enzyme activity and mitochondrial membrane potential. Taking together, all the results, confirming each other, showed that the combination of the imatinib and bortezomib has considerable synergistic effects on the apoptosis through increase in caspase-3 enzyme activity and decrease in mitochondrial membrane potential in human K562 CML cells.
A Comparative Study on the Efficacy of Some Artemisinin Combination Therapies on Plasmodium berghei in Swiss Albino Mice  [PDF]
U. O. Georgewill, O. O. Ebong
Pharmacology & Pharmacy (PP) , 2012, DOI: 10.4236/pp.2012.31016
Abstract: This study evaluated and compared the efficacy of five brands of Artemisinin Combination Therapies (ACTs); Dihydroartemisinin plus Piperaquine, Artesunate plus Amodiaquine, Artesunate plus Sulphadoxine/Pyrimethamine, Artemether plus lumefantrine and Artesunate plus mefloquine combinations in vivo in P.berghei infected swiss albino mice. The experimental animals were pre-screened to rule out infection. All drugs were administered as clinical doses for the curative test and the Mean Percentage Parasitemia level assessed daily for seven days and on day 60. The results showed that all the drugs were effective with artesunate plus amodiaquine combination being the most efficacious followed by dihydroartemisinin plus piperaquine and artesunate plus sulphadoxine plus pyrimethamine combinations followed by artesunate plus mefloquine combination and artemether plus lumefantrine combination which was the least efficacious. Results on day 60 showed increasing parasitemia levels in mice which received Artemether plus lumefantrine and Artesunate plus mefloquine combinations which is indicative of recrudescence. The results of this study showed that the ACT’s used in the experiment were all efficacious. The possible development of resistance to some of the drugs was shown by the increasing parasitemia levels following treatment with artesunate plus lumefantrine and artesunate plus mefloquine combinations on day 60.
Intravesical Treatment with Vorinostat Can Prevent Tumor Progression in MNU Induced Bladder Cancer  [PDF]
Degui Wang, Siwei Ouyang, Yingxia Tian, Yan Yang, Bo Li, Xiangwen Liu, Yanfeng Song
Journal of Cancer Therapy (JCT) , 2013, DOI: 10.4236/jct.2013.46A3001
Abstract:

Background: Histone deacetylase inhibitors (HDACI) are promising class of drugs acting as antiproliferative agents by promoting differentiation as well as inducing apoptosis. Vorinostat (suberoylanilide hydroxamic acid, SAHA) is the first among this new class of anticancer drugs to be approved by FDA for the treatment of cancer but only for cutaneous T cell lymphoma (CTCL). The objective of this study is to investigate the inhibitory effect of SAHA on the viability of human bladder cancer cells and its synergetic effect with chemotherapy agents in vitro and in vivo. Methods: The cell viability of human bladder cancer cell lines after treated with SAHA or SAHA combining mitomycin c (MMC), Cisplatin (DDP) and Adriamycin (ADM) were determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Hoechst staining was used to observe cell morphology for apoptotic cells. The survivin protein and acetylated histone H3 levels in bladder cancer were quantified by Western blot analysis. In vivo tumor growth inhibition of intravesical inject SAHA was determined in rats with N-methyl-N-nitrosourea (MNU) induced bladder cancer. Results: SAHA significantly inhibited growth of bladder cancer cell lines with concentration and time dependent manner. Furthermore, better results of tumor inhibition would be achieved when it was combined with chemotherapeutic agents in vitro and in vivo. Survivin expression decreased and acetylated histone H3 expression increased in bladder cancer cells lines after SAHA treatment. Intravesically injections of SAHA can inhibit tumor progress when combined with DDP. Conclusions: SAHA can act as HDACI which has direct anti-cancer effect and can enhance the action of several chemotherapy agents markedly. SAHA may sensitize bladder cancer to anti cancer drugs by down regulating survivin

Role of Combination Chemotherapy with 5-Fluorouracil, Cisplatin and Paclitaxel for Advanced Gall Bladder Cancer  [PDF]
Mumtaz Ahmad Ansari, Satyendra K. Tiwary, Uday Pratap Shahi, Vijay K. Shukla
Journal of Cancer Therapy (JCT) , 2014, DOI: 10.4236/jct.2014.53032
Abstract:

Aim: The prognosis for patients with advanced Gallbladder carcinoma is poor. Due to unresectability and relatively ineffective chemotherapy available, a need exists for effective chemotherapeutic regimen. The aim of this study was to determine the efficacy and safety profile of 5-fluorouracil, cisplatin and paclitaxel in patients with advanced Gallbladder cancer. Material and Methods: From January 2002 to July 2004, 40 patients of advanced carcinoma Gallbladder received 5-fluorouracil, cisplatin and paclitaxel. On day 1, paclitaxel was given (150 mg/m2), cisplatin was given on day 2 (50 mg/m2) and 5-fluorouracil was given from day 1 to day 3 (500 mg/m2). This cycle was repeated every three weeks and patient assessment was done. Results: Forty patients were enrolled in this study. Thirty-five were assessed for response. Five patients were lost in follow up. There were thirty females and ten males. A median of three cycles of treatment (range one to seven) was administered. Two patients achieved complete response and eleven had partial responses giving an overall response rate of 32.5% in the intention-to-treat population (95% confidence interval 11.1% to 46.5%). The median response duration was 5.3 months. The median time to progression and overall survival was 4.1 months and 11.2

Combined Therapy of Pioglitazone and Atorvastatin Alleviate Diabetes in Rats More Effectively than That of Mono Therapy  [PDF]
Hazrat Ali, A. F. M. Towheedur Rahman, Saiful Islam, Al Mamun, Shaheda Zannah, A. H. M. Khurshid Alam, Aziz Abdur Rahman, Mamunur Rashid
Pharmacology & Pharmacy (PP) , 2014, DOI: 10.4236/pp.2014.55060
Abstract:

Present research was designated to investigate the hypoglycemic, hypolipidemic and antioxidant activity of the combination of pioglitazone and atorvastatin on long-term alloxan-induced diabetes rats (AIDRs). The experiments were carried out to determine blood glucose level, lipid profile, free radial scavenging activities, superoxide dismutase (SOD) and catalase in liver tissue. In addition, left ventricular (LV) hypertrophy and cardiomyocyte size were also determined by histological analysis. It was found that in short-term induction, pioglitazone significantly reduced the blood glucose level without having any considerable effect on lipid profile and antioxidant enzymes (SOD and catalase) in rats. On the other hand, atorvastatin significantly reduced total cholesterol (TC), triglyceride (TG) and low density lipoprotein cholesterol (LDL-C) with marked increase in the level of high density lipoprotein cholesterol (HDL-C) and improved activity of SOD and catalase enzymes. However, pathological changes of heart and pancreas were not observed after short-term exposure to alloxan in rats. Long-term diabetes induction resulted in LV hypertrophy and prominent shrinkage of islets of Langerhans cells. Treatment with atorvastatin in combination with pioglitazone significantly reduced the LV hypertrophy, TC, TG and LDL level whereas they noticeably increased HDL level, DPPH (1,1-Diphenyl-2-picryl-hydrazyl) free radical scavenging activity, SOD and catalase activity with satisfactory recovery of Langerhans cells. The result demonstrated that combination therapy was more effective than that of mono-therapy for preventing diabetes with cardiovascular diseases (CVD) in rats.

Simvastatin Potentiates the Antihyperglycemic, Antidyslipidimic and Antioxidative Effect of Glibenclamide on Alloxan-Induced Diabetic Rats  [PDF]
Mst. Marium Begum, A. F. M. Towheedur Rahman, Saiful Islam, Md. Asaduzzaman, Hazrat Ali, Shaheda Zannah, A. H. M. Khurshid Alam, Md. Aziz Abdur Rahman, Mamunur Rashid, Yusuf Ali
Pharmacology & Pharmacy (PP) , 2014, DOI: 10.4236/pp.2014.511115
Abstract: The aim of the current study is to investigate the effect of combination of glibenclamide; an antidiabetic drug and simvastatin; a HMG-CoA reductase inhibitor on long-term (four weeks) alloxan-induced diabetes rats (ADRs). Methods: Alloxan (120 mg/kg body weight, BW) was injected intra-peritonially (i.p.) in rats. At first alloxan (120 mg/kg BW) induced diabetic rats were treated with single dose of glibenclamide (1.2 mg/70kg BW) and simvastatin (10 mg/70kg BW) for two weeks. Then fixed dose combinations of glibenclamide (0.6 mg/70kg BW) and simvastatin (5 mg/70kg BW) were injected along with those of two drugs for four weeks. Results: At first it was found that glibenclamide reduced significant amount of glucose in blood, but it had no significant effect on lipid profile on short term (two weeks) ADRs. In contrast, simvastatin had no effect on blood glucose level, whereas it significantly reduced total cholesterol (TC), triglycerides (TG) and low density lipoprotein cholesterol (LDL-C) and increased significant amount of high density lipoprotein cholesterol (HDL-C). However, pathological changes of pancreas’s Islets of Langerhans were observed only after long-term (four weeks) induction of alloxan in rats. The inhibitory effect of combination therapy on blood glucose, TC, TG and LDL-C level was higher than those of monotherapy alone on long term ADRs. In addition, treatment with combination therapy on long term ADRs showed higher amount of HDL-C level and super oxide dismutase and catalase enzyme activity than those with monotherapy. They also decreased serum glutamic pyruvic transaminase (SGPT) and Serum glutamic oxaloacetic transaminase (SGOT) level. Administration of simvastatin recovered Langerhans cells from shrinkage whereas glibenclamide displayed slight recovery. But the combination therapy showed complete recovery of Langerhans cells as compared with diabetic rats. Conclusion: Our present findings suggest that treatment of glibenclamide in combination with simvastatin may be more effective than mono-therapy for preventing diabetes in rats. It may also suggest that this combination may have some beneficial effects on reducing cardiovascular risks from long term diabetes in rats.
盗用他人医保卡号冒名取药的行为如何定罪
How to Convict the Imposter Who Embezzles Medical Insurance Card Number to Pick Up the Medicine
 [PDF]

刘斌
Dispute Settlement (DS) , 2016, DOI: 10.12677/DS.2016.23006
Abstract:
盗用他人医保卡号冒名取药的行为构成何种犯罪,我国刑法并没有对此作出特别规定,这种欺盗结合型犯罪,犯罪人的行为中既有秘密窃取的行为,又有欺骗的行为,是手段与目的的牵连关系。区分关键在于两种行为之间哪种行为为哪种行为创造了条件,行为人取得财物是在被害人处于何种情形之下取得的。
In China’s Criminal Law, there are no specific rules on how to convict the imposter who embezzles medical insurance card number to pick up the medicine. It is a kind of crime combing fraud and embezzlement. The crime behaviors include both secretly stealing and fraudulent conduct, re-flecting the relationship between means and ends. The keys are to distinguish which behavior creates conditions for another behavior, and the perpetrator obtains property in what kind of sit-uation that the victim faces.
Page 1 /2133
Display every page Item


Home
Copyright © 2008-2017 Open Access Library. All rights reserved.